#drug-pricing-deal

#drug-pricing-deal

According to the patent, a specific crystalline form of the drug known as polymorph C may be more effective than other versions because it is absorbed more efficiently by the body. The patent also notes that laboratory studies showed the drug reduced tumor growth and helped mice with brain tumors live longer, prompting early clinical trials to test whether the treatment is safe and effective in humans.

The IRA requires drugmakers to sell selected patented drugs to the government for its Medicare Parts B & D programs at a stipulated "maximum fair price". If they don't agree to these prices, then they face tax penalties on sales of the drug exceeding their profits from it, or the exclusion of all their drugs from Medicare and Medicaid purchases. This would foreclose access to up to 160 million patients, accounting for around 40% of US prescription drug spending or 20% of global prescription drug spending.

The idea echoes a policy implemented during his first term, when Trump suggested that requiring hospitals to post their charges online could ease one of the most common gripes about the health care system the lack of upfront prices. To anyone who's gotten a bill three months after treatment only to find mysterious charges, the idea seemed intuitive. "You're able to go online and compare all of the hospitals and the doctors and the prices,"

When generic drug manufacturers have issues like contamination, it is difficult for those who take the medications to know if they are affected. There is no standardized way to look up the data for where the pills in your bottle came from. ProPublica made an app that makes the lookup more straightforward. Even though generic drugs make up 90% of prescriptions dispensed in the U.S., the FDA only provides piecemeal information about them.

The 340B program allows hospitals to buy outpatient drugs at steep discounts, with the purported purpose of helping them fund care for low-income and uninsured patients. The now-axed rebate model would have invited drugmakers to participate voluntarily in a rebate-based discount system. Basically, instead of the provider receiving a discount upfront at purchase, the 340B discount would be applied after purchase via rebate - and subject to tedious data submission requirements.

The U.S. Food and Drug Administration is reportedly mulling whether more prescription drugs should be sold over the counter (OTC) at pharmacies. In an interview on Wednesday, FDA commissioner Martin Makary told CNBC that everything should be over the counter except drugs that are deemed unsafe or addictive or that require clinical monitoring. Makary said the agency is reviewing how it decides which drugs can be sold with or without a prescription from a health care practitioner.

For years, Congress has signaled that it wants to crack down on Pharmacy Benefit Managers, the middle men that have come under fire for their vertical integration with insurers and their role in spiking drug costs. This week, it finally happened via the Consolidated Appropriations Act of 2026, promptingemployer groups including the Purchaser Business Group on Health (PBGH) and the ERISA Industry Committee to cheer its passage.